Introduction
Nontuberculous mycobacteria are ubiquitous and transmitted to humans through the environment from sources like water and soil, causing infections in different areas of the body, but mainly pulmonary, skin, soft tissue infections, and lymphadenitis [1] . Mycobacterium triplex is a slow growing, nonpigmented, nontuberculous mycobacterium, described in 1996 from clinical strains of different geographical locations in the United States [2] . This species is related to Mycobacterium simiae, Mycobacterium lentiflavum, and Mycobacterium sherrisii, but more closely to Mycobacterium genavense [3] .
Only a few cases of M. triplex infections have been reported in the United States and Europe. To our knowledge, this is the first report of M. triplex infection in a country of Latin America. This study was approved by the ENSP-Fiocruz Committee for Ethical Research with human beings. 
Methods
The patient studied was clinically, laboratorial, and radiological assessed at diagnosis. Monthly cultures were performed to monitor the progress of treatment in Hospital Sanató rio Partenon in Porto Alegre, Rio Grande do Sul state, Brazil.
Two sputum isolates were obtained according of American Thoracic Society microbiologic criteria for nontuberculous mycobacterial lung disease [4] and processed at the central laboratory of Rio Grande do Sul, Brazil, in the period of 2007-2008. After growth in Lö wenstein-Jensen medium, the cultures were sent to the Centro de Referê ncia Professor Hé lio Fraga/ENSP/FIOCRUZ for identification, but the PRA-hsp65 methodology did not allow for identification at species level.
To clarify the identity and to characterize the isolates, phenotypic and sequencing assays were performed in the laboratory of Centro de Referê ncia. The two isolates were designated as HF1226 and HF2396 and tested for pigment production and growth rate at 35-37°C. The following biochemical tests were performed: nitrate reduction, niacin production, heat-stable catalase (68°C), arylsulfatase activity (at 3 days), Tween 80 hydrolysis, and urease. The isolates were slow growing and nonpigmentated. The biochemical profile was positive for nitrate reduction, heat-stable catalase, and urease, and negative for niacin, 3 days arylsulfatase, and Tween 80 hydrolysis. Part of the RNA polymerase betasubunit gene (rpoB), the 16S-23S internal transcribed spacer, and the 441 bp fragment of the 65 kDa heat shock protein gene (hsp65) were sequenced using previously published approaches [5] [6] [7] .
Results and discussion
The 51-year-old Caucasian woman studied had been treated for tuberculosis three times in the past. The patient presented with a productive cough and night sweats and her CD4 count was 514 cells/mL. She was being treated for human immunodeficiency virus with antiretroviral therapy (zidovudine, lamivudine, and tenofovir). The sputum smear microscopy showed acid-fast bacilli (+) in two samples. A chest X-ray revealed bilateral pulmonary lesions (nodular opacities and cavities). She was empirically prescribed amikacin, ofloxacin, ethambutol, and clarithromycin, since there was no identification of mycobacteria. No sensitivity test was conducted. During follow-up, her respiratory symptoms improved and periodic respiratory specimen cultures tested negative. She was considered cured after 18 months of treatment.
The 16S rDNA gene was sequenced using MicroSEQ Full Gene 16S rDNA Kit (Life Technologies, Carlsbad, CA, USA), as indicated by the manufacturer. All the sequences were compared on identity with the ones of the closest reference strains using a basic local alignment search tool (BLAST) search [8] . The sequences of reference type strains (retrieved from GenBank) and strain HF1226 (the older of the two isolates) were used to build a concatenated neighbor-joining tree [9] using the MEGA version 6 program [10] . Comparison with the reference strains present in GenBank through a BLAST search showed that the 16S rDNA (accession number KF856620), hsp65 (KF856621), and internal transcribed spacer (KF856623) sequences of the isolates have 100% identity with M. triplex type strain (ATCC 700071), but the rpoB (KF856622) gene presented two mismatches when compared with M. triplex type strain (99.72% identity). The next high similarity was that of Mycobacterium florentinum type strain DSM 44852 with nine mismatches and 95.92% identity. The phylogenetic tree revealed that strain HF1226 was clustered (with 100% bootstrap) to the type strain of M. triplex and distinct from other related species (Fig. 1) .
All phenotypic results were the same as described for the M. triplex type strain [2] . The molecular and phylogenetic analysis of the two isolates from the Brazilian patient confirmed the identification as M. triplex. BLAST analysis also revealed that the polymorphisms identified in the rpoB gene of these two strains had never been described, as no identical sequence was found in the database.
M. triplex has been suggested as a cause of disease in severely immunocompromised patients, but can also affect immunocompetent individuals [11, 12] . Symptoms and radiological findings of the studied patient are similar to those in previous reports. There are few reported cases of Figure 1 -Phylogenetic concatenated tree using 16S rDNA, hsp65, rpoB, and internal transcribed spacer sequences, constructed using neighbor-joining method and Kimura's two-parameter as the substitution model. The bootstrap values, calculated on 1000 replicates, indicated the significance of branches. Mycobacterium tuberculosis sequence was used as the outgroup. M. = Mycobacterium.
M. triplex infections to date. In Europe, M. triplex has been reported as causing pulmonary infection in patients of countries such as Italy, Portugal, Ireland, and Finland [12] [13] [14] [15] . In the United States, a study described a case of M. triplex that was isolated from the pericardial and peritoneal fluid of a liver transplant patient [16] . Also, in the United States another study identified eight M. triplex strains from clinical M. simiae complex isolates [17] . There are extremely rare reports of patients infected by M. triplex outside Europe and the United States; one exception is a Nigerian human immunodeficiency virus positive man with central nervous system involvement [18] .
The results presented in this study extend the range of geographical distribution of M. triplex. This finding increases the possibility of the diagnosis of new cases of M. triplex infection in Latin America, especially in Brazil.
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